Variable |
Healthy individuals |
Uninfected
two-dose vaccinees |
Uninfected three-dose vaccinees |
Uninfected four-mixed-dose vaccinees |
Number of participants |
10 |
8 |
10 |
4 |
Age (years), median (range) |
41 (33-63) |
35 (32-50) |
/ |
31
(28-51) |
Sex at birth, female |
7 (70%) |
7 (88%) |
/ |
2
(50%) |
COVID vaccination history |
|
|
|
|
Inactivated vaccines |
0 |
8 (100%) |
10 (100%) |
0 |
Ad5-nCOV (adenovirus vector vaccine) |
0 |
0 |
0 |
0 |
dNS1-RBD |
0 |
0 |
0 |
0 |
Recombinant Fusion Protein |
0 |
0 |
0 |
0 |
Three-dose inactivated vaccines plus one-dose dNS1-RBD
|
0
|
0
|
0
|
1 (25%)
|
Three-dose inactivated vaccines plus one-dose Ad5-nCOV
|
0
|
0
|
0
|
2 (50%)
|
Three-dose inactivated vaccines plus one-dose Recombinant Fusion Protein
|
0
|
0
|
0
|
1 (25%)
|
Time between last vaccination and serum sampling |
N/A |
2-3
weeks |
3-5 months |
2-4 weeks |